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Background:  Ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) generates inorganic pyrophosphate, a solute that 
serves as an essential physiological inhibitor of calcification. Inactivating mutations of ENPP1 are associated with generalized 
calcification in infancy and an increased risk of developing type 2 diabetes mellitus (T2DM). We hypothesized that the ENPP1 
K121Q variant may be associated with increased coronary artery calcification in T2DM patients. 
Methods:  The study subjects were aged 34 to 85 years and showed no evidence of clinical cardiovascular disease prior to recruit-
ment. A total of 140 patients with T2DM were assessed for their coronary artery calcium (CAC) scores and ENPP1 K121Q poly-
morphisms were identified.
Results:  The prevalence of subjects carrying the KQ genotype was 12.9% (n = 18). There were no 121QQ homozygotes. Patients 
with the KQ genotype did not show a significantly higher CAC score (122 vs. 18; P = 0.858). We matched each patient with the   
KQ genotype to a respective control with the KK genotype by gender, age, and duration of diabetes. When compared to matched 
controls, we observed no significant difference in CAC score (P = 0.959).
Conclusions:  The ENPP1 K121Q polymorphism does not appear to be associated with coronary artery calcification in patients 
with T2DM.
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INTRODUCTION
As in bone remodeling, vascular calcification is regulated by 
several physiological inhibitors, such as osteopontin, fetuin-A, 
and ectonucleotide pyrophosphatase/phosphodiesterase-1 
(ENPP1) [1,2]. ENPP1 generates inorganic pyrophosphate 
(PPi), a solute that serves as an essential physiological inhibitor 
of calcification. Pyrophosphate levels, which are maintained by 
the activity of ENPP1, can be metabolized by alkaline phos-
phatase (ALP) into phosphate, a promoter of calcification. A 
balance between ectonucleotidase and ALP might be crucial 
in controlling the calcification process.
  Vascular calcification frequently develops in patients with 
diabetes mellitus resulting in an increased risk of cardiovascu-
lar events. The coronary artery calcium (CAC) scores mea-
sured by computed tomography is an excellent marker for the 
overall coronary atherosclerotic burden [3], and is an inde-
pendent predictor even in asymptomatic diabetic patients [4]. 
Inactivating mutations of ENPP1 are associated with general-
ized calcification in infancy [5] and, interestingly, risk of de-
veloping type 2 diabetes mellitus (T2DM) [6-8]. These associ-
ations have been attributed to the direct interaction of ENPP1 
with the α-subunit of insulin receptors [7]. A functional mis-
sense DNA polymorphism in exon 4 that causes an amino acid 
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change from lysine to glutamine at codon 121 (K121Q) has 
been associated with insulin resistance in several populations 
[6,9-11]. Furthermore, Q variant carriers are associated with an 
early onset of coronary artery disease in Caucasians [7,12].
  Eller et al. [13] reported that patients who are heterozygous 
for the ENPP1 K121Q polymorphism have higher coronary 
calcification scores and increased aortic stiffness in patients 
with end-stage renal failure. However, patients with chronic 
renal disease have an abnormal calcium phosphate homeosta-
sis, and the CAC results might be confounded by deranged 
mineral metabolism. To our knowledge, no data are available 
on the association between ENPP1 K121Q polymorphism and 
severity of coronary artery calcifications in T2DM patients or 
even in healthy subjects. Recently, Lee et al. [14] reported that 
aortic arch calcification, which was measured qualitatively (all 
or none) using a plain chest radiograph, is associated with the 
Q allele in healthy Korean subjects. However, the limited reso-
lution of plain X-rays may render an inconsistent and relative-
ly low sensitivity detection for aortic calcification [15], not to 
mention that this feature is an indirect marker of coronary 
atherosclerosis, in contrast with direct quantification of CAC.
  We evaluated whether or not the ENPP1 K121Q polymor-
phism is associated with increased coronary artery calcification 
in patients with T2DM who showed no evidence of clinical 
cardiovascular disease. Confirmation of this association would 
suggest that genotyping of the ENPP1 gene could be useful in 
risk stratification for cardiovascular events in patients with 
T2DM.
METHODS
Study subjects
This study was carried out on 150 patients with T2DM who vis-
ited the diabetes clinic at Kangwon National University Hospital 
between March and June 2007, and who agreed to participate 
upon our explanation of the purpose and procedures of the 
study. Diagnosis of T2DM was done in accordance with the 
diagnostic criteria established by the American Diabetes As-
sociation in 1997. Patients who showed typical symptoms of 
ischemic heart disease or who had previously received coro-
nary angiography or cardiovascular intervention were exclud-
ed. We also excluded patients with an accompanying chronic 
disease such as chronic liver disease, chronic kidney disease 
where serum creatinine (Cr) levels exceed 2.0 mg/dL, chronic 
obstructive pulmonary disease, or chronic arthritis. Also ex-
cluded were those with an accompanying endocrine disease 
such as hypothyroidism, hyperparathyroidism, or Cushing’s 
syndrome. We analyzed the results from 140 subjects as 8 of 
the original 150 subjects did not undergo testing despite their 
agreement to do so, and 2 subjects were confirmed to have hy-
pothyroidism and idiopathic hypoparathyroidism following 
study completion. This study was approved by the Institution-
al Review Board at Kangwon National University Hospital. 
Quantification of CAC scores and laboratory 
measurements
We carried out our interviews and physical examinations to-
gether with a review of the subjects’ medical records. We ex-
amined if the subjects had cardiovascular disease, history of 
smoking, and the duration of diabetes, and obtained individu-
al body mass index. We also measured the waist circumference 
of each subject and measured blood pressure twice, 5 minutes 
apart, with the patient in a stable state, using a hemodyna-
mometer (Omron HEM-780; Omron Healthcare Co. Ltd., Kyo-
to, Japan). The mean value of the two measurements was then 
used in analysis. For the CAC score, we measured both area 
and volume using multi-slice computed tomography (MSCT) 
(LightSpeed Plus; GE Medical Systems, Milwaukee, WI, USA), 
and used the measured value for volume in our statistical pro-
cess. Conditions under which we collected information when 
taking the MSCT were similar to those employed in our previ-
ous article [16]. Blood sampling was done following an 8-hour 
fast. General chemistry, serum lipid test, microalbuminuria, 
and high sensitivity C-reactive protein (hs-CRP) tests were 
carried out. For hs-CRP testing, we used Latex agglutination 
method that can detect levels as low as 0.01 mg/dL. If a patient 
was affected by an acute episode, laboratory results for at least 1 
month following complete resolution of the episode were ex-
cluded from the data collection.
Genotyping
We analyzed genotype using a commercialized 5΄ nuclease as-
say method. We separated the buffy coat from the subject’s ve-
nous blood sample and, then stored them at -80°C. We ex-
tracted genomic DNA from the above samples using a DNA 
purification kit. SNP genotyping of rs1044498 in exon 4 of the 
ENPP1 gene was performed using allelic discrimination Taq-
Man
® SNP Genotyping Assays (Assay ID: C_1207994_20; Ap-
plied Biosystems, Foster City, CA, USA). All primers and probes 
were obtained from Applied Biosystems. Real-time PCR was 322
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carried out in a final volume of 20 µL, containing a 2 µM con-
centration of each probe, 5 µM forward and reverse primers, 1 
× PCR Master Mix (Applied Biosystems), and 10 ng genomic 
DNA. Using the 7300 real-time PCR system (Applied Biosys-
tems), we measured fluorescence intensity, and using automated 
software, we determined genotype.
Statistical analyses
In genotype analysis, we ran χ
2 verification to check if the al-
lelic frequency of the gene conformed to the Hardy-Weinberg 
equilibrium. To check if an association existed between gene 
polymorphism and the CAC score, we performed multiple re-
gression analysis taking age, body mass index, waist circumfer-
ence, and the duration of diabetes, which are known as influ-
encing factors on coronary arterial calcification, as covariates.
  For comparison of wild type and variant, we matched to 
each patient with the KQ genotype to a respective control with 
the KK genotype using a stratified random selection method 
by age, gender, and the duration of diabetes, owing to too 
small a number of subjects with the KQ genotype compared to 
that of the 121KK genotype (Fig. 1). This design was adopted 
from the study by Eller et al. [13]. Differences in mean values 
between the two groups with different ENPP1 genotypes were 
determined using unpaired Student’s t-test, and those of medi-
ans with the Mann-Whitney U test. The χ
2 test was used to 
compare categorical variables such as smoking history and 
medications used at enrollment. We used the SPSS version 
12.0 software program (SPSS Inc., Chicago, IL, USA) and de-
termined P value significance for values less than 0.05.
RESULTS
The mean age of the subjects was 62.1 ± 8.2 years and the mean 
duration of diabetes was 9.4 ± 7.1 years. The mean body mass 
Table 1.  Baseline characteristics of the study subjects
No. 140 
Sex, M/F 80/60 
Age, yr 62.1 ± 8.2 
Duration of diabetes, yr 9.4 ± 7.1 
Smoking, n (%) 
Non-smoker 
Ex-smoker 
Current smoker 
76 (54.3) 
24 (17.1) 
40 (28.6) 
BMI, kg/m
2 25.3 ± 3.0 
Waist circumference, cm  89.0 ± 7.4 
SBP, mm Hg  132 ± 16 
DBP, mmHg 79 ± 9 
FBS, mg/dL 139 ± 34 
HbA1C, % 7.3 ± 1.1 
Albumin-adjusted calcium, mg/dL  9.3 ± 0.3 
Phosphorus, mg/dL 3.6 ± 0.6 
Ca×P, mg
2/dL
2 33.0 ± 5.5 
hs-CRP
a, mg/dL  0.08 (0.04, 0.19) 
Serum creatinine, mg/dL 1.0 ± 0.2 
Microalbuminuria
a, mg/g creatinine  14.8 (7.0, 31.2) 
Total cholesterol, mg/dL 181 ± 31 
Triglyceride, mg/dL  147 ± 79 
HDL-C, mg/dL  47 ± 10 
LDL-C, mg/dL 109 ± 27 
CAC scoresa, AU  16.5 (0, 128.8) 
Medications when enrolled, n (%)
Sulfonyureas
Metformin
Glitazone
Insulin
Statin
Antihypertensives
b
Aspirin
97 (69.3)
110 (78.6)
33 (23.6)
15 (10.7)
29 (20.7)
82 (58.6)
30 (21.4)
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; Ca×P, calcium phosphorus product; FBS, fasting 
blood sugar; HbA1C, hemoglobin A1C; hs-CRP, high sensitivity C-
reactive protein; HDL-C, high density lipoprotein cholesterol; LDL-
C, low density lipoprotein cholesterol; CAC, coronary artery calcium.
aMedian and inter-quartile ranges of hs-CRP, microalbuminuria, 
CAC scores, 
bAntihypertensives included ACE inhibitor, Angiotensin 
receptor blocker ARB, Calcium-channel blocker, and thiazides.
Fig. 1.  ENPP1 K121Q genotype and matching each patient 
with the KQ genotype (n = 18) with an subject with the KK 
genotype. T2DM, type 2 diabetes mellitus.
140 patients with
T2DM
18 patients with
the KQ genotype
18 patients 
enrolled
122 patients with
the KK genotype
18 patients 
matched
0 patients with
the QQ genotype323
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index was 25.3 ± 3.0 kg/m
2 and mean value of waist circumfer-
ence was 89.0 ± 7.4 cm. Detailed characteristics of the subjects 
are shown on Table 1. A total of 46 patients (32.9%) had no CAC 
(< 0 AU, Agatston Unit); the remaining 94 patients (67.1%) had 
varying degrees of CAC. According to the guidelines on the 
interpretation of calcium scores proposed by Rumberger et al. 
[17], lesions were minimal (score, 1 to 10) in 16 subjects (11.4%), 
mild (score, 11 to 100) in 34 subjects (24.3%), moderate (score, 
Table 2.  Comparison of clinical characteristics of matched subjects according to ENPP1 genotypes 
KK (n = 18)  KQ (n = 18)  P value
Sex, M/F 13/5  13/5 
Age, yr 60.2 ± 7.0  60.4 ± 7.6  0.927
Duration of diabetes, yr 9.8 ± 6.4  11.1 ± 9.5  0.626
Smoking, n (%) 0.875
a
Non-smoker  8 (44) 8 (44)
Ex-smoker  3 (17) 2 (11)
Current smoker  7 (39) 8 (44)
BMI, kg/m
2  24.7 ± 2.9 25.1 ± 3.5 0.704
Waist circumference, cm  86.9 ± 8.2 88.2 ± 9.6 0.658
SBP, mm Hg 137 ± 17 133 ± 18 0.461
DBP, mm Hg 84 ± 9  79 ± 11  0.104
FBS, mg/dL 144 ± 31  140 ± 21  0.676
HbA1C, % 7.0 ± 1.1  7.5 ± 1.0  0.156
Albumin-adjusted calcium, mg/dL  9.2 ± 0.2 9.2 ± 0.3 0.442
Phosphorus, mg/dL  3.4 ± 0.6 3.5 ± 0.3 0.724
Ca×P, mg
2/dL
2 31.1 ± 4.98 31.9 ± 3.24 0.575
hs-CRP
b, mg/dL 0.08 (0.03, 0.19) 0.09 (0.05, 0.21)  0.449
Serum creatinine, mg/dL 1.1 ± 0.1  1.1 ± 0.2  0.916
Microalbuminuria
b, mg/g creatinine  15.8 (10.4, 30.2)  17.0 (5.8, 27.6) 0.895
Total cholesterol, mg/dL 175 ± 38  167 ± 25  0.467
Triglyceride, mg/dL 197 ± 138  133 ± 62  0.084
HDL-C, mg/dL 42 ± 10  45 ± 12  0.419
LDL-C, mg/dL 103 ± 29  98 ± 19  0.618
CAC scores
b, AU  13.5 (0, 102.5) 23.5 (0, 155.0) 0.269
Medications when enrolled, n (%) 1.0
a
Sulfonyureas 14 (78) 14 (78)
Metformin 14 (78) 15 (83)
Glitazone 2 (11) 2 (11)
Insulin 2 (11) 2 (11)
Statin 2 (11) 3 (17)
Antihypertensives
C 9 (50) 9 (50)
Aspirin 4 (22) 3 (17)
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBS, fasting blood sugar; HbA1C, hemoglobin A1C; hs-
CRP, high sensitivity C-reactive protein; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; CAC, coro-
nary artery calcium.
aχ
2 test, 
bMedian and inter-quartile ranges of hs-CRP, microalbuminuria, and CAC scores, 
cAntihypertensives included ACE inhibitor, Angio-
tensin receptor blocker ARB, Calcium-channel blocker, and thiazides.324
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101 to 400) in 31 subjects (22.1%), and severe with a high prob-
ability for stenosis (score, > 400) in 13 subjects (9.3%). The me-
dian CAC score was 16.5 AU (interquartile range, 0 to 128.8). 
  The allele distribution of study subjects was in Hardy-Wein-
berg equilibrium (χ
2 = 0.66, P = 0.72). The frequency of minor 
allelic gene variation was 0.064. The distribution of the ENPP1 
K121Q alleles in the study subjects was as follows: 122/140 
(87.1%) were homozygous for the KK genotype, 18/140 (12.9 
%) were heterozygous, and there were no homozygous sub-
jects for the QQ genotype (Fig. 1). There were no significant 
differences in the clinical and biochemical characteristics and 
CAC scores between the KK genotype groups and KQ geno-
type groups (Tables 2 and 3).
  Each patient with the KQ genotype (n = 18) was matched 
with a control subject with the KK genotype by age, gender, 
and duration of diabetes in a 1:1 study design (Fig. 1), as de-
scribed in the methods section. There were no significant dif-
ferences in blood pressure, A1C levels, smoking habits, serum 
calcium, serum phosphate, microalbuminuria, lipid profiles, 
and use of oral antidiabetic medications and statins between 
the two groups with different ENPP1 genotypes. We did not 
find any significant differences in the CAC scores between the 
two ENPP1 genotype groups (Table 4).
DISCUSSION
To summarize the results of this study, coronary artery calcifi-
cation was observed in 67% of the study subjects, and no sig-
nificant association was observed between ENPP1 K121Q 
genotypes and coronary artery calcification scores. 
  Vascular calcification is widespread in patients with athero-
sclerosis, T2DM, and end-stage renal disease, although the 
mechanisms may differ in each of these disease contexts. As in 
skeletal calcifications, vascular calcification is governed by pos-
itive and negative regulators, and under normal conditions, 
constitutive inhibition dominates. The balance between levels 
of inorganic phosphate and pyrophosphates determine wheth-
er hydroxyapatite mineral crystals form and grow in cartilage 
and bone. Under certain physiological conditions, calcifica-
tion is inhibited by extracellular PPi through cleavage of nu-
cleotide triphosphates by ENPP1 and cellular export. The ex-
tracellular PPi levels are reduced, and calcification can proceed. 
As described earlier, there have been several in vitro and in vivo 
studies demonstrating associations between vascular calcifica-
tion and a deficiency of ENPP1 and/or mutations of ENPP1 
genotypes; however, we know of no previous studies that have 
investigated the association of the ENPP1 K121Q polymor-
phism with the severity of coronary artery calcifications in 
T2DM patients, or even in healthy subjects.
  To date, few clinical studies have investigated the relationship 
between vascular calcification and genetic polymorphisms, al-
though these have been extensively demonstrated in non-dia-
betic subjects. In type 2 diabetic patients, several genetic varia-
tions related to calcium metabolism are reportedly associated 
with coronary artery calcifications. Polymorphisms of α2-
Heremans-Schmid (AHSG) glycoprotein, traditionally known 
as fetuin-A, which is an important mineralization inhibitor, 
were associated with CAC scores in European Americans with 
T2DM [18]. It was thought that this result was consistent with 
the known biological role of AHSG in vascular calcification. 
The concentration of circulating fetuin-A protein has been 
shown to predict the risk of vascular calcification, inflamma-
tion, and all-cause and cardiovascular disease mortality. This 
is especially true for patients with end-stage renal disease [19]. 
However, this association was not consistent across various 
ethnic populations. In the recent Diabetes Heart Study [20], 
bone morphogenetic protein 7 gene polymorphisms were re-
ported to be associated with inverse relationships between vas-
cular calcification and bone mineral density. Bone morphoge-
netic protein has been proposed to play an inhibitory role in 
vascular calcification, but its inhibitory effect has not been ex-
Table 3.  Regression analysis of CACs and ENPP1 gene 
K121Q polymorphisms for all study subjects (n = 140) con-
trolling for age, body mass index, waist circumference and du-
ration of diabetes 
Gene SNP Genotype No. Log (CACs+1) P value
ENPP1 K121Q KK 122 1.24 ± 1.06 0.902
KQ 18 1.19 ± 1.07
QQ 0 -
CACs, coronary artery calcium scores.
Table 4.  Regression analysis of CAC and ENPP1 gene K121Q 
polymorphisms for matched subjects (n = 36) controlling for 
age, body mass index, waist circumference and duration of di-
abetes 
Gene SNP Genotype No. Log (CACs+1) P value
ENPP1 K121Q KK 18 1.17 ± 1.20 0.676
KQ 18 1.19 ± 1.07
CACs, coronary artery calcium scores.325
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tensively studied.
  Our data indicate that the 121Q variant of the ENPP1 gene 
is not associated with coronary artery calcification scores in 
patients with T2DM. This may be a result of several factors, 
including sample size, concurrent medications, unknown dis-
turbed mineral metabolism, and other hormonal and genetic 
effects. The Q allele frequency in our study was 0.064, and there 
was no QQ homozygote. This very low minor allele frequency 
in our study subjects is similar to that recently reported in a 
study of a Korean cohort population [14]. These authors re-
ported that the minor allele frequency of ENPP1 121Q is 0.031 
in healthy subjects and 0.084 in type 2 diabetic patients, with 
no QQ homozygote. This frequency was lower than among 
Caucasians (23.2-36.4%) [9,10], South Asian Indians (27.5-
34.2%) [6], and Chinese (18.8%) [21]. We assume that these 
differences of allele frequencies among ethnic groups might 
play certain roles in the association of CAC scores and ENPP1 
genotypes. Small sample size and the lack of homozygous car-
riers of the ENPP1 K121Q genotype is an important limitation 
of our study.
  Medications at enrollment, which included statins, may also 
affect vascular pathology. However, there are no reports that 
statins might influence the forming of CAC and the progres-
sion of calcium deposition in vascular beds. Statins significantly 
lower low density lipoprotein cholesterol and reduce atheroma 
formation but are largely powerless against extensive calcifica-
tion [22]. Coronary artery calcification is common and pro-
gressive in young adults with end-stage renal disease who have 
been undergoing dialysis for years [23]. Whether a disturbed 
mineral metabolism might exist in type 2 diabetic patients with 
apparently normal serum creatinine levels is largely unknown. 
In our study, there was no difference in serum calcium or phos-
phate level between the genotype groups. Calcium-phosphate 
product, a marker of extraskeletal calcification, which should 
be maintained at less than 55 mg
2/dL
2 in patients with chronic 
kidney disease, was also within normal range and showed no 
differences between the two genotype groups.
  Lee et al. [14] reported that ENPP1 K121Q polymorphisms 
are associated with T2DM and that the Q allele is associated 
with increased aortic arch calcification in a Korean popula-
tion. However, they did not measure coronary artery calcifica-
tion scores, as in our study, and unfortunately the measurement 
of calcification was not quantitative but qualitative, which they 
mentioned as a limitation of their study.
  The limitations of this study are, first, a possible selection 
bias due to the fact that our subjects were not from the general 
population group but were visiting patients to a single hospi-
tal. However, the possibility of selection bias for genotype in 
our study is less likely because the distribution of genotype was 
within the Hardy-Weinberg equilibrium. Also, the minor al-
lele frequency in our study is within the range reported by an-
other study of a Korean population [14]. Secondly, the study 
subjects were medicated with several anti-diabetics, antihy-
pertensives, and statins; however, there were no differences in 
medications at enrollment between comparison groups. In 
fact, the medication might affect the vascular calcification pro-
cess; however, for ethical reasons, a non-medicated study could 
not be allowed in patients with T2DM. Third, we had statisti-
cal difficulties in comparing the groups due to low authenticity 
caused by the relatively small population and due to a low fre-
quency of gene variants. These problems could be resolved with 
further study using a greater number of subjects. In conclusion, 
we did not observe an association between K121Q polymor-
phism of ENPP1 and CAC scores in Korean type 2 diabetic pa-
tients.
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